drugset / Trial / NCT06118762
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the treatment of metastatic colorectal cancer that progressed or could not be tolerated after previous fluorouracil, oxaliplatin, and irinotecan based therapy
Timeline
- Start
- 2023-10-20
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Subject | Raltitrexed | Small molecule | 3 mg/m2 | Intravenous |